Endocannabinoids control spasticity in a multiple sclerosis model - Wikidata - awgldk - TriplyDB

Endocannabinoids control spasticity in a multiple sclerosis model

Endocannabinoids control spasticity in a multiple sclerosis model

http://www.wikidata.org/entity/Q28142626

about

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review The endocannabinoid system as an emerging target of pharmacotherapy Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system.Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids.Neuroprotective therapies after perinatal hypoxic-ischemic brain injury.Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality The endocannabinoid system as a target for the treatment of neurodegenerative disease.Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.Cannabinoid control of neuroinflammation related to multiple sclerosis.Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 Cannabinoids and neuroinflammation.New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis Manipulation of the endocannabinoid system by a general anaesthetic Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors T-cell-mediated disruption of the neuronal microtubule network: correlation with early reversible axonal dysfunction in acute experimental autoimmune encephalomyelitis.Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures.The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism.The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.Brain 2-Arachidonoylglycerol Levels Are Dramatically and Rapidly Increased Under Acute Ischemia-Injury Which Is Prevented by Microwave Irradiation.Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.P2X7 receptors control 2-arachidonoylglycerol production by microglial cells.The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies.Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury.TRPV1 gates tissue access and sustains pathogenicity in autoimmune encephalitis.

P2860

Q21261356-47B5D8CA-DD2E-4485-BDE1-F2867C1515BC Q24648473-FE1ABF90-1470-49C0-9A69-50AA4258EBE3 Q26770823-60D6DB2D-8EDB-4F54-B725-77D19DD42973 Q26776171-235FE20A-641B-4DD5-AEFE-4A4F476E13DD Q26801046-8A67DAE0-A059-4E69-B5FA-353CAFAC1A50 Q28345762-A0CF69FB-3E65-4250-8567-17F71A3E1A7F Q28366593-C2637F21-029E-4292-881F-042B8B080EDA Q30391852-51C025CA-49A6-479C-A295-55C516744497 Q30433284-528CE3DF-9E55-48EB-BCF9-91691823119F Q30493991-618E9E85-94B5-4B40-9F6B-5379C6317D13 Q31122398-95B03313-4370-4CDF-9BB4-D816DA8FA6F3 Q33715420-25AB6947-8760-410D-9F17-25F4ED216FA7 Q33772042-2C4FEC18-04DC-4784-9D27-EF2EBAEEB62E Q33793559-A03C8879-AF9A-4FFC-B389-BCA6EB976DC5 Q34018061-874CE239-2E39-46FD-87B1-2E855407BC17 Q34098196-FD7A8CF3-31B1-437D-B3B2-4029D9C3A7E4 Q34574015-FD451BE5-5449-4C17-BB5A-024EDB4498E0 Q34583231-EA172A31-F6EC-473F-868F-C7150B669C94 Q34597537-958B6B7F-4561-47A9-972E-F1BDCB766850 Q34912871-EDF69687-94F6-420D-912D-2A06C080136D Q35046205-46175424-6318-4BD7-80A0-DBE8BB433EC3 Q35098586-F4E878A7-98F4-4265-AF5D-55517FFDE348 Q35168593-286585D6-FB69-4103-AC39-0A6A66582FC8 Q35213727-039008CD-DDA1-4C3C-B186-91AE156B2D23 Q35222043-C4991646-0B77-43BE-925E-B56615EDBC6E Q35674014-865A6CD5-D606-4571-8573-DC865B71F2BA Q35989527-C2D548FA-950D-4FBA-9D4F-0AEEE79374DF Q36094329-C130B5F6-9841-40EE-89DA-FF004DAEDB2A Q36178329-19A6071F-69FF-4679-9A01-EF40B80AE2F2 Q36341688-58C553CB-7102-4B5C-BBFF-7EBA4DAF378D Q36348374-4F3DAFDD-2E64-4DA9-B66B-CF70C5EE5844 Q36416340-6A8C8524-7299-429C-9B8E-DC7E8C7B5E99 Q36591816-0C7773A9-E85A-4496-92C9-D3276E05AE45 Q36759329-CA7D4E14-A32A-481A-A061-63B92A8FC8A8 Q36775237-CFDC4F1D-A427-4305-A29C-EB57A1628525 Q36854779-61EC97FE-349D-4E64-992A-47C0C1BD7305 Q36943243-A5DF9B34-C885-4BCB-A616-8328C78AE26B Q36949750-C8D80782-9F6D-4019-B06E-ABB74F4657F8 Q36961126-F6B20AFB-9D5B-4E4B-934C-717463218B80 Q37100271-ECF20A9C-A316-4F11-B245-F58F61D7A70C

P2860

Endocannabinoids control spasticity in a multiple sclerosis model

http://www.wikidata.org/entity/Q28142626

description

2001 nî lūn-bûn

@nan

2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Endocannabinoids control spasticity in a multiple sclerosis model

@ast

Endocannabinoids control spasticity in a multiple sclerosis model

@en

Endocannabinoids control spasticity in a multiple sclerosis model

@nl

type

label

Endocannabinoids control spasticity in a multiple sclerosis model

@ast

Endocannabinoids control spasticity in a multiple sclerosis model

@en

Endocannabinoids control spasticity in a multiple sclerosis model

@nl

prefLabel

Endocannabinoids control spasticity in a multiple sclerosis model

@ast

Endocannabinoids control spasticity in a multiple sclerosis model

@en

Endocannabinoids control spasticity in a multiple sclerosis model

@nl

P1433

Q28142626-69191B0B-C433-415D-BA3C-EB5752D570D1

P1476

Q28142626-15CA03FD-2D78-428C-BFAC-0DC54740E0CD

P2093

Q28142626-277439FC-F44A-4F71-B0C3-79F33AC26DD9

Q28142626-29C5DAD5-6234-4DBE-B50B-2F43945FB052

Q28142626-2EB254DF-F3ED-4BC4-850A-1140DCA604FF

Q28142626-4172D3C1-D280-48D9-9B49-4E840F0F6C4F

Q28142626-47B360DC-92CC-452A-B0CB-AC4EE85108BC

Q28142626-94B3160C-4014-4F93-A729-A824CA8D1087

Q28142626-99910D33-E937-4DFD-8572-29A70D66759A

Q28142626-9D962049-031C-4299-8244-E0726CA01202

Q28142626-9E6ACA11-E243-4C87-8CE1-A1B006977C80

Q28142626-A2E1446D-7B51-4266-8B77-1E6E4D3B39CA

P304

Q28142626-30FEEAD7-2B4B-4947-828C-1B78981A0D06

P31

Q28142626-4DF4B4DE-06B5-4AF5-983B-5326A08C3BF5

P3181

Q28142626-78D9FD85-288D-491C-92E9-2966135C229A

P356

Q28142626-A612A5C4-2F70-4F9C-8723-C5307ABBDAF3

P407

Q28142626-9495C2AD-4662-46C7-B331-BE57A3D9E986

P433

Q28142626-46742379-FB90-4C6D-90F0-EDC9E882D4BD

P478

Q28142626-FF960A9B-592B-4BF1-AFE0-0B2EFAE72CF9

P50

Q28142626-CF0628E0-462E-4BE3-880E-C99346CD4DAC

P577

Q28142626-EFA43975-C940-4F9D-BF97-074D183E634B

P5875

Q28142626-9B3F45FB-9341-4BFF-B9A2-69431B95F568

P698

Q28142626-B6A520DF-42C7-4426-A30B-A9B822B86FF9

P921

Q28142626-A601D01D-E580-482C-AD24-2DA07175B11E

Q28142626-C0C11C94-F091-428A-9783-3A710CD46878

P3181

P356

P1433

P1476

Endocannabinoids control spasticity in a multiple sclerosis model

@en

P2093

A Khanolkar

http://www.w3.org/2001/XMLSchema#string

D Baker

http://www.w3.org/2001/XMLSchema#string

F Fezza

http://www.w3.org/2001/XMLSchema#string

G Pryce

http://www.w3.org/2001/XMLSchema#string

J L Croxford

http://www.w3.org/2001/XMLSchema#string

L Layward

http://www.w3.org/2001/XMLSchema#string

P Brown

http://www.w3.org/2001/XMLSchema#string

R G Pertwee

http://www.w3.org/2001/XMLSchema#string

T Bisogno

http://www.w3.org/2001/XMLSchema#string

V Di Marzo

http://www.w3.org/2001/XMLSchema#string

P304

300-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3698259

http://www.w3.org/2001/XMLSchema#string

P356

10.1096/FJ.00-0399FJE

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Alexandros Makriyannis

P577

2001-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12172580

http://www.w3.org/2001/XMLSchema#string

P698

11156943

http://www.w3.org/2001/XMLSchema#string

P921

endocannabinoids

multiple sclerosis